Breaking News Instant updates and real-time market news.

TEVA

Teva

$14.37

-0.1 (-0.69%)

, MYL

Mylan

$22.18

-0.57 (-2.51%)

09:15
05/13/19
05/13
09:15
05/13/19
09:15

Fly Intel: Pre-market Movers

HIGHER: Amber Road (AMBR), up 27% after E2open announced a deal to acquire the company in an all-cash transaction valued at approximately $425M... Shell Midstream (SHLX), up 6% after entering into an agreement to acquire Shell's 25.97% equity interest in Explorer Pipeline and 10.13% equity interest in Colonial Pipeline for $800M. LOWER: Uber (UBER), down 7% in its second day of trading after its disappointing IPO on Friday... Weatherford (WFT), down 58% after announcing plans to restructure through a Chapter 11 bankruptcy filing... Veritiv (VRTV), down 3% after BofA/Merrill analyst John Babcock downgraded the stock to Neutral from Buy and lowered its price target to $26 from $37... Teva (TEVA) and Mylan (MYL), down 10% and 3%, respectively, after Connecticut Attorney General William Tong led a 44-state coalition in announcing a lawsuit against Teva and 19 other generic drug manufacturers alleging a "broad conspiracy to artificially inflate and manipulate prices, reduce competition and unreasonably restrain trade for more than 100 different generic drugs."

TEVA

Teva

$14.37

-0.1 (-0.69%)

MYL

Mylan

$22.18

-0.57 (-2.51%)

AMBR

Amber Road

$10.26

0.7 (7.32%)

SHLX

Shell Midstream

$20.19

0.19 (0.95%)

UBER

Uber

$41.55

(0.00%)

WFT

Weatherford

$0.36

-0.0224 (-5.86%)

VRTV

Veritiv

$24.72

0.79 (3.30%)

  • 14

    May

  • 30

    May

  • 31

    May

TEVA Teva
$14.37

-0.1 (-0.69%)

05/03/19
CANT
05/03/19
NO CHANGE
Target $16
CANT
Neutral
Teva price target lowered to $16 from $25 at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen lowered her price target for Teva Pharmaceutical to $16 from $25 and keeps a Neutral rating on the shares following the company's Q1 results. The analyst would like to see increased sales and earnings visibility before getting more positive on the stock.
05/01/19
WELS
05/01/19
NO CHANGE
Target $18
WELS
Market Perform
Teva shares reflect much of bad news, says Wells Fargo
Wells Fargo analyst David Morris kept his Market Perform rating and $18 price target on Teva (TEVA) ahead of its Q1 earnings tomorrow, saying investors have "low expectations" for the quarter after "weak-ish" Sandoz results from Novartis (NVS). The analyst also points to IQVIA (IQV) sales and prescriptions data indicating that Teva generic sales were down 12% in March, 10% in February, and 13% in January, though the decline are "much smaller" than seen in U.S. generics during 2018. Morris further expects Teva to address the risk of opioid litigation that became a concern during the quarter in its earnings call.
04/24/19
WELS
04/24/19
NO CHANGE
WELS
Sandoz results should not be seen as positive for generics, says Wells Fargo
Wells Fargo analyst David Maris sees nothing in the Q1 results from Novartis (NVS) unit Sandoz that points to a dramatically improving U.S. generic pricing environment. We would tot read the Sandoz results as a positive for generic companies such as Teva (TEVA) and Mylan (MYL), and commentary about generic Copxone pricing trends is a negative, Maris tells investors in a research note. He believes Sandoz trends are important to watch as a potential read-through for other generic drug company results. Novartis continues to see higher generic headwinds in the remainder of 2019, Maris points out, citing comments from the earnings call.
04/22/19
CANT
04/22/19
NO CHANGE
Target $75
CANT
Overweight
Emergent shares largely pricing in Teva approval, says Cantor Fitzgerald
The FDA on Friday granted Teva Pharmaceutical (TEVA) final approval for its generic version of Narcan, Cantor Fitzgerald analyst Brandon Folkes tells investors in a research note. The analyst views the announcement as largely anticipated following the expiration of Teva's 30- month stay last month. Shares of Emergent BioSolutions (EBS) are down 18.7% since reporting Q4 earnings, largely driven by the anticipation of a final approval of Teva's generic naloxone, says Folkes. While Friday's approval is a negative and will continue to create an overhang on Emergent shares, the recent weakness has "adequately accounted for this overhang," he contends. As such, Folkes keeps an Overweight rating on Emergent BioSolutions with a $75 price target.
MYL Mylan
$22.18

-0.57 (-2.51%)

05/08/19
RBCM
05/08/19
NO CHANGE
Target $26
RBCM
Outperform
Mylan price target lowered to $26 from $45 at RBC Capital
RBC Capital analyst Randall Stanicky lowered his price target on Mylan to $26, saying yesterday's 24% stock price plunge and investor frustration are "justified", even though the magnitude of the sell-off may be "overly punitive." The analyst cites the management's forecasting challenges, "delays in responding to industry change", and governance issues as factors in the stock price decline. Stanicky also keeps his Outperform rating and expects the pressure on the company's board to facilitate change to increase.
05/08/19
05/08/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Mylan (MYL) downgraded to Market Perform from Outperform at Wells Fargo with analyst David Maris saying Mylan reported "disappointing" results which missed consensus on several key metrics including revenue and revenue by segment. 2. Inogen (INGN) downgraded to Neutral from Overweight at JPMorgan with analyst Robert Marcus saying the company's in-line Q1 results were overshadowed by a $25M reduction to guidance. 3. Fortive (FTV) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Joshua Pokrzywinski citing the stock's valuation after a 29% year-to-date advance as well as the sector valuation of "high quality industrials". 4. Farmer Bros. (FARM) downgraded to Neutral from Buy at Roth Capital with analyst Gerry Sweeney saying the company's results were hurt by significant operating issues and Mike Keown stepped down as CEO. 5. 2U (TWOU) downgraded to Neutral from Outperform at Credit Suisse with analyst Brad Zelnick noting the company reported Q1 and lowered its fiscal year revenue guidance, primarily accounting for schools tightening their admissions. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/07/19
WELS
05/07/19
DOWNGRADE
Target $22
WELS
Market Perform
Mylan downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst David Maris downgraded Mylan to Market Perform from Outperform and lowered his price target for the shares to $22 from $33.
05/08/19
WELS
05/08/19
DOWNGRADE
Target $22
WELS
Market Perform
Wells Fargo downgrades Mylan to Market Perform after 'disappointing' quarter
Wells Fargo analyst David Maris downgraded Mylan to Market Perform from Outperform and lowered his price target for the shares to $22 from $33. The stock closed yesterday down 24%, or $6.73, to $21.53. Mylan reported "disappointing" results which missed consensus on several key metrics including revenue and revenue by segment, Maris tells investors in a research note. The analyst says he's downgrading the shares as Mylan continues to perform below his expectations. Even after yesterday's selloff, Maris believes the risks outweigh the valuation given the earnings uncertainty. Further, the lack of any outcome or major announcement about the strategic review suggests the review is not going to result in any material changes, according to Maris.
AMBR Amber Road
$10.26

0.7 (7.32%)

SHLX Shell Midstream
$20.19

0.19 (0.95%)

11/06/18
RBCM
11/06/18
DOWNGRADE
RBCM
Sector Perform
Shell Midstream downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital analyst TJ Schultz downgraded Shell Midstream to Sector Perform and lowered his price target to $22 from $27, saying the stock is likely to trade "sideways for a while" given continued uncertainty regarding its joint venture Zydeco co-owned by Shell Midstream and Shell Pipeline. The analyst adds that Shell's commitment to the current stock structure "signals a delay to a long-term solution".
12/10/18
BOFA
12/10/18
DOWNGRADE
BOFA
Underperform
Shell Midstream downgraded to Underperform from Neutral at BofA/Merrill
10/10/18
FBCO
10/10/18
INITIATION
Target $24
FBCO
Neutral
Shell Midstream initiated with a Neutral at Credit Suisse
Credit Suisse analyst Spiro Dounis initiated Shell Midstream with a Neutral rating and a price target of $24.
03/13/19
JPMS
03/13/19
DOWNGRADE
Target $23
JPMS
Neutral
Shell Midstream downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Jeremy Tonet downgraded Shell Midstream Partners to Neutral from Overweight and lowered his price target for the shares to $23 from $25. The analyst views a near-term full incentive distribution right resolution as doubtful given the temporary IDR waiver. This likely limits "positive re-rating potential for some time as more investors actively avoid IDRs," Tonet tells investors in a research note.
UBER Uber
$41.55

(0.00%)

05/10/19
WEDB
05/10/19
NO CHANGE
Target $65
WEDB
Outperform
Uber's conservative pricing 'smart and prudent,' says Wedbush
Wedbush analyst Ygal Arounian maintained an Outperform rating on Uber (UBER) with a $65 price target after the ride-hailing company's IPO priced at $45 per share, valuating the company north of $80B. In a research note to investors, Arounian says he views Uber's conservative pricing as a "smart and prudent" strategy coming out of the box as it clearly learned from its "little brother" Lyft (LYFT), and the experience it has gone through over the past month. Arounian says he views Lyft as a "one trick pony" domestic ride sharing player and believes Uber has clearly established itself as the clear #1 player in the ridesharing industry and is paving a similar road to what Amazon (AMZN) did to transform retail and ecommerce and Facebook (FB) did for social media.
05/08/19
PIPR
05/08/19
NO CHANGE
Target $78
PIPR
Overweight
Lyft reported strong quarter out of the gates, says Piper Jaffray
Lyft reported revenue and adjusted EBITDA ahead of consensus, while also guiding both Q2 and fiscal 2019 above the Street, Piper Jaffray analyst Michael Olson tells investors in a research note partially titled "Strong Out of the Gates." The company indicated that, while it continues to spend aggressively on various initiatives, the competitive pressure on rider incentives for core ridesharing has receded to some degree, adds Olson. He sees this as a sign of a rational duopoly between Lyft and Uber (UBER) for the time being. The analyst recommends owning Lyft shares as these levels and maintains an Overweight rating on the name with a $78 price target.
05/03/19
05/03/19
INITIATION

Fly Intel: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Lyft (LYFT) initiated with an Underweight at Atlantic Equities. 2. Contura Energy (CTRA) initiated with a Buy at Seaport Global. 3. Uber (UBER) initiated with a Neutral at Atlantic Equities. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/03/19
ATLE
05/03/19
INITIATION
Target $55
ATLE
Neutral
Atlantic starts Uber with Neutral rating despite preferring over Lyft
Atlantic Equities analyst James Cordwell initiated coverage of Uber (UBER) with a Neutral rating and $55 price target ahead of the company's initial public offering. The analyst this morning also initiated coverage of Lyft (LYFT) with an Underweight rating and $50 price target. Transportation-as-a-service addresses a large market opportunity, says the analyst, whose analysis shows that scale enables superior returns and a clearer path to profitability. Given the benefits of scale, Cordwell prefers Uber to Lyft, due to the company's "market-leading ridehailing position augmented by the fast-growing Eats business and freight brokerage opportunity." The analyst's year-end 2019 price target of $55 for Uber implies 0.9 times fiscal 2020 gross bookings, which he notes is similar to the historical average multiple of Amazon's (AMZN) e-commerce business.
WFT Weatherford
$0.36

-0.0224 (-5.86%)

01/17/19
STFL
01/17/19
NO CHANGE
STFL
Stifel lowers Oilfield Services and Equipment estimates
Stifel analyst Stephen Gengaro said he expects overall E&P capital spending to be about flat in the U.S. market and he cut his forecast for U.S. drilling and completion activity based on the current WTI crude oil strip. He lowered his U.S rig count projections by 50 to 1,050 rigs in 2019 and by 100 to 1,150 rigs in 2020 and he cut his 2019 EBITDA forecast by roughly 10% on average. Based on the changes in estimates, Gengaro lowered his earnings expectations for the majority of the names he covers and cut his price targets on several. Among the largest target changes, he lowered his price target on Core Laboratories (CLB) to $86 from $110, cut his target on Emerge Energy (EMES) to $3 from $5, reduced his target on Halliburton (HAL) to $37 from $45 and trimmed his target on Superior Energy (SPN) to $5 from $9. Others in the space that Gengaro covers include Baker Hughes (BHGE), DMC Global (BOOM), Civeo (CVEO), Keane Group (FRAC), FTS International (FTSI), Liberty Oilfield Services (LBRT), National Oilwell (NOV), Oil States (OIS), Pioneer Energy (PES), ProPetro Holding (PUMP), RPC, Inc. (RES), Schlumberger (SLB), U.S. Silica (SLCA), Smart Sand (SND), Solaris Oilfield (SOI), Tenaris (TS), Tetra Technologies (TTI) and Weatherford (WFT).
01/10/19
01/10/19
DOWNGRADE
Target $1

Market Perform
Weatherford downgraded to Market Perform from Outperform at BMO Capital
As previously reported, BMO Capital analyst Daniel Boyd downgraded Weatherford to Market Perform and lowered his price target to $1.00 from $2.50. The analyst says the stock represents a "call-option on the oil cycle", but sees that option "suffering from time decay" and an adverse macro environment. Boyd further acknowledges that the stock has "significant" upside if the company can "endure", but also points to its continued challenges with its $8B gross debt load.
01/10/19
01/10/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Lockheed Martin (LMT) downgraded to Equal Weight from Overweight at Morgan Stanley. 2. JetBlue (JBLU) downgraded to Neutral from Overweight at JPMorgan with analyst Jamie Baker lowering his price target for the shares to $18 from $20. 3. Weatherford (WFT) downgraded to Market Perform from Outperform at BMO Capital with analyst Daniel Boyd saying the stock represents a "call-option on the oil cycle," but sees that option "suffering from time decay" and an adverse macro environment. 4. Yelp (YELP) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Brian Nowak saying he identified three building revenue headwinds that he believes will lead to negative revisions and underperformance of the stock. 5. Dollar Tree (DLTR) downgraded to Perform from Outperform at Oppenheimer with analyst Rupesh Parikh saying he now views shares as fully valued and sees the case for upside as less attractive. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/16/19
SOCO
01/16/19
DOWNGRADE
SOCO
Equalweight
Weatherford downgraded to Equalweight from Overweight at Capital One
VRTV Veritiv
$24.72

0.79 (3.30%)

03/06/19
RHCO
03/06/19
NO CHANGE
Target $30
RHCO
Hold
Veritiv price target lowered to $30 from $35 at SunTrust
SunTrust analyst Keith Hughes lowered his price target on Veritiv to $30 and kept his Hold rating after its Q4 results, saying that while revenue saw modest growth, the company's "ongoing weak trends in Facilities Maintenance limited margin expansion". The analyst notes that although Veritiv anticipates 2019 EBITDA growth and "substantial improvement" in free cash flows, he sees expansion potential as limited based on the "mixed trends" and higher Packaging segment cost headwinds.
03/05/19
03/05/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Alnylam (ALNY) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst David Lebowitz saying he expects Onpattro to ultimately exceed the Street's expectations for 2019 given early metrics about the drug's launch. 2. Ctrip (CTRP) upgraded to Overweight from Neutral at JPMorgan, to Overweight from Equal Weight at Morgan Stanley, to Buy from Neutral at Citi, and to Buy from Underperform at CLSA. 3. Ingersoll-Rand (IR) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Joe Ritchie saying his conviction in Ingersoll-Rand has strengthened in light of a strong order book exiting 2018, improving price/cost, and a conservative guidance range. 4. ImmunoGen (IMGN) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Matthew Harrison saying while he expects ImmunoGen to be skewed higher in the next few weeks as investors assess the potential to negotiate with the FDA to file based on the FRalpha-high cohort alone, Harrison said he has limited hope for such a filing. 5. Veritiv (VRTV) upgraded to Buy from Neutral at BofA/Merrill with analyst John Babcock saying he expects an inflection in free cash flow and believes 2019 EBITDA and free cash flow guidance are achievable. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/13/19
BOFA
05/13/19
DOWNGRADE
Target $26
BOFA
Neutral
Veritiv downgraded to Neutral at BofA/Merrill
As previously reported, BofA/Merrill analyst John Babcock downgraded Veritiv to Neutral from Buy and lowered its price target to $26 from $37. The analyst cut estimates to the low-end of the reduced adjusted EBITDA guidance range of $165M-180M, down from $190M-$200M, and sees limited catalysts to drive shares higher.
05/13/19
BOFA
05/13/19
DOWNGRADE
BOFA
Neutral
Veritiv downgraded to Neutral from Buy at BofA/Merrill

TODAY'S FREE FLY STORIES

VJET

Voxeljet

$1.64

-0.05 (-2.96%)

18:44
08/18/19
08/18
18:44
08/18/19
18:44
Recommendations
Voxeljet analyst commentary at Piper Jaffray »

Voxeljet price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSNLF

Samsung

$0.00

(0.00%)

, AAPL

Apple

$206.44

4.71 (2.33%)

18:40
08/18/19
08/18
18:40
08/18/19
18:40
Periodicals
Apple CEO warns Trump about China tariffs, Reuters reports »

President Donald Trump…

SSNLF

Samsung

$0.00

(0.00%)

AAPL

Apple

$206.44

4.71 (2.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

T

AT&T

$34.98

0.64 (1.86%)

, CMCSA

Comcast

$43.17

0.82 (1.94%)

18:05
08/18/19
08/18
18:05
08/18/19
18:05
On The Fly
Box Office Battle: 'Good Boys' wins weekend with $21M debut »

"Box Office Battle" is…

T

AT&T

$34.98

0.64 (1.86%)

CMCSA

Comcast

$43.17

0.82 (1.94%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$55.72

0.64 (1.16%)

LGF.A

Lionsgate

$11.06

0.02 (0.18%)

LGF.B

Lionsgate

$10.52

0.01 (0.10%)

DIS

Disney

$135.19

1.79 (1.34%)

VIAB

Viacom

$26.02

0.09 (0.35%)

VIA

Viacom

$27.27

-0.4 (-1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 23

    Oct

  • 27

    Oct

SFTBF

SoftBank

$0.00

(0.00%)

, SFTBY

SoftBank

$0.00

(0.00%)

17:59
08/18/19
08/18
17:59
08/18/19
17:59
Periodicals
Softbank plans to lend up to $20B to employees to invest in new fund, WSJ says »

Softbank is planning to…

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

16:50
08/18/19
08/18
16:50
08/18/19
16:50
Periodicals
Trump administration to give Huawei more time to work with U.S. clients,WSJ says »

The Trump administration…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JSAIY

J Sainsbury

$0.00

(0.00%)

16:46
08/18/19
08/18
16:46
08/18/19
16:46
Periodicals
J Sainsbury's not talking to internal candidates for CEO succession,Reuters says »

J Sainsbury's is not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$219.92

4.27 (1.98%)

16:39
08/18/19
08/18
16:39
08/18/19
16:39
Hot Stocks
Tesla relaunching solar-panel business with no-contract rentals »

Tesla is now offering…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 23

    Sep

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

16:14
08/18/19
08/18
16:14
08/18/19
16:14
Periodicals
White House says no recession in sight, Reuters reports »

White House officials…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$89.46

0.91 (1.03%)

16:11
08/18/19
08/18
16:11
08/18/19
16:11
Periodicals
Novartis executive sold shares before data manipulation made public,Reuters says »

An unnamed Novartis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 25

    Sep

MO

Altria Group

$46.48

1 (2.20%)

16:08
08/18/19
08/18
16:08
08/18/19
16:08
Periodicals
CDC investigating lung illness linked to e-cigarette use, Reuters reports »

The Centers for Disease…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CFB

CrossFirst Bancshares

$14.61

(0.00%)

, JFU

9F Inc

$10.09

0.52 (5.43%)

08:48
08/18/19
08/18
08:48
08/18/19
08:48
On The Fly
Opening Day: CrossFirst rises after setting IPO share price lower than expected »

Shares of CrossFirst…

CFB

CrossFirst Bancshares

$14.61

(0.00%)

JFU

9F Inc

$10.09

0.52 (5.43%)

NET

Cloudflare

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

SDC

SmileDirectClub

$0.00

(0.00%)

AMZN

Amazon.com

$1,791.82

16.72 (0.94%)

MSFT

Microsoft

$136.13

2.39 (1.79%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 10

    Sep

  • 27

    Oct

CBS

CBS

$43.83

0.5 (1.15%)

, VIA

Viacom

$27.27

-0.4 (-1.45%)

08:03
08/17/19
08/17
08:03
08/17/19
08:03
Periodicals
Viacom-CBS merger got panned by investors, Barron's says »

CBS (CBS) and Viacom…

CBS

CBS

$43.83

0.5 (1.15%)

VIA

Viacom

$27.27

-0.4 (-1.45%)

VIAB

Viacom

$26.02

0.09 (0.35%)

AAPL

Apple

$206.44

4.71 (2.33%)

DIS

Disney

$135.19

1.79 (1.34%)

T

AT&T

$34.98

0.64 (1.86%)

CMCSA

Comcast

$43.17

0.82 (1.94%)

CMCSK

Comcast

$0.00

(0.00%)

NFLX

Netflix

$302.74

6.81 (2.30%)

AMZN

Amazon.com

$1,791.82

16.72 (0.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 05

    Sep

  • 23

    Sep

  • 23

    Oct

  • 27

    Oct

MYGN

Myriad Genetics

$25.36

2.14 (9.22%)

07:57
08/17/19
08/17
07:57
08/17/19
07:57
Periodicals
Myriad Genetics stock might have an FDA issue, Barron's says »

Myriad Genetics plunged…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

CSCO

Cisco

$46.96

0.73 (1.58%)

, NTAP

NetApp

$46.75

0.33 (0.71%)

07:50
08/17/19
08/17
07:50
08/17/19
07:50
Periodicals
Trade war hitting tech stocks, Barron's says »

Cisco (CSCO) plunged 9% a…

CSCO

Cisco

$46.96

0.73 (1.58%)

NTAP

NetApp

$46.75

0.33 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 12

    Sep

  • 10

    Oct

  • 13

    Nov

RDS.A

Royal Dutch Shell

$55.55

0.47 (0.85%)

, RDS.B

Royal Dutch Shell

$55.56

0.46 (0.83%)

07:47
08/17/19
08/17
07:47
08/17/19
07:47
Periodicals
Investors should not abandon oil, gas stocks, Barron's says »

Energy stocks have rarely…

RDS.A

Royal Dutch Shell

$55.55

0.47 (0.85%)

RDS.B

Royal Dutch Shell

$55.56

0.46 (0.83%)

BP

BP

$36.27

0.22 (0.61%)

XOM

Exxon Mobil

$68.30

1.06 (1.58%)

CVX

Chevron

$115.79

0.08 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 25

    Sep

TGT

Target

$84.20

1.67 (2.02%)

, WMT

Walmart

$112.99

0.32 (0.28%)

07:40
08/17/19
08/17
07:40
08/17/19
07:40
Periodicals
Grocery Outlet thriving as rivals struggle, Barron's says »

While Dow was down 800…

TGT

Target

$84.20

1.67 (2.02%)

WMT

Walmart

$112.99

0.32 (0.28%)

GO

Grocery Outlet

$46.55

2.81 (6.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

AEO

American Eagle

$15.40

0.63 (4.27%)

07:33
08/17/19
08/17
07:33
08/17/19
07:33
Periodicals
American Eagle to soar despite trade war, Barron's says »

American Eagle's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 25

    Sep

ANGI

Angi Homeservices

$8.18

-0.18 (-2.15%)

, MTCH

Match Group

$84.53

2.08 (2.52%)

07:27
08/17/19
08/17
07:27
08/17/19
07:27
Periodicals
Dating business might be IAC's best asset, greatest challenge, Barron's says »

IAC (IAC) has rallied 34%…

ANGI

Angi Homeservices

$8.18

-0.18 (-2.15%)

MTCH

Match Group

$84.53

2.08 (2.52%)

IAC

IAC

$249.17

4.21 (1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 10

    Sep

  • 10

    Oct

AAPL

Apple

$206.44

4.71 (2.33%)

, HAS

Hasbro

$114.29

1.13 (1.00%)

07:13
08/17/19
08/17
07:13
08/17/19
07:13
On The Fly
Week in review How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$206.44

4.71 (2.33%)

HAS

Hasbro

$114.29

1.13 (1.00%)

MAT

Mattel

$10.74

(0.00%)

AGR

Avangrid

$49.29

0.37 (0.76%)

JPM

JPMorgan

$107.73

2.52 (2.40%)

BAC

Bank of America

$27.04

0.79 (3.01%)

C

Citi

$63.46

2.13 (3.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 09

    Sep

  • 02

    Oct

  • 15

    Oct

  • 15

    Oct

  • 16

    Oct

  • 27

    Oct

NCLH

Norwegian Cruise Line

$50.48

1.38 (2.81%)

18:04
08/16/19
08/16
18:04
08/16/19
18:04
Hot Stocks
Norwegian Cruise Line CEO sells 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RM

Regional Management

$27.12

0.14 (0.52%)

18:01
08/16/19
08/16
18:01
08/16/19
18:01
Hot Stocks
Regional Management CFO buys 5K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

RTN

Raytheon

$178.10

-0.42 (-0.24%)

17:59
08/16/19
08/16
17:59
08/16/19
17:59
Hot Stocks
Raytheon awarded $199.59M Navy contract for MK 15 CIWS »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEN

Wendy's

$19.94

0.16 (0.81%)

17:57
08/16/19
08/16
17:57
08/16/19
17:57
Hot Stocks
Breaking Hot Stocks news story on Wendy's »

Trian Fund lowers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

BRY

Berry Petroleum

$8.59

0.39 (4.76%)

17:54
08/16/19
08/16
17:54
08/16/19
17:54
Syndicate
Breaking Syndicate news story on Berry Petroleum »

Berry Petroleum files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSWI

CSW Industrials

$70.20

1.92 (2.81%)

17:52
08/16/19
08/16
17:52
08/16/19
17:52
Hot Stocks
CSW Industrials CEO sells 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.